Xeris Biopharma (NASDAQ:XERS) Stock Price Up 5.7% – Still a Buy?

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) was up 5.7% during mid-day trading on Friday . The stock traded as high as $3.60 and last traded at $3.55. Approximately 1,281,332 shares were traded during trading, a decline of 8% from the average daily volume of 1,395,790 shares. The stock had previously closed at $3.36.

Analyst Ratings Changes

A number of research analysts recently commented on XERS shares. HC Wainwright increased their price target on shares of Xeris Biopharma from $6.00 to $6.60 and gave the company a “buy” rating in a report on Monday, November 11th. Piper Sandler lowered Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 price objective for the company. in a research note on Monday, November 11th.

Xeris Biopharma Trading Up 3.6 %

The stock has a market capitalization of $518.80 million, a PE ratio of -7.73 and a beta of 2.62. The business’s 50 day moving average is $3.34 and its 200 day moving average is $2.90.

Institutional Investors Weigh In On Xeris Biopharma

Hedge funds and other institutional investors have recently modified their holdings of the business. Wealth Enhancement Advisory Services LLC purchased a new position in Xeris Biopharma during the 3rd quarter valued at $35,000. Quantbot Technologies LP bought a new stake in shares of Xeris Biopharma during the third quarter worth $44,000. Asset Management Group Inc. boosted its stake in shares of Xeris Biopharma by 130.7% during the second quarter. Asset Management Group Inc. now owns 26,480 shares of the company’s stock valued at $60,000 after purchasing an additional 15,000 shares during the period. Sanctuary Advisors LLC bought a new position in shares of Xeris Biopharma in the second quarter worth about $75,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in Xeris Biopharma by 64.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 28,657 shares of the company’s stock worth $82,000 after buying an additional 11,239 shares during the period. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.